Studies of 18F-FDG Radiologic Tracer in Metastatic Prostate Cancer
| Author and year | n | Clinical state | Study | Purpose and endpoint | Statistical method | Conclusion |
|---|---|---|---|---|---|---|
| Schöder et al. (40), 2005 | 91 | Rising PSA | Retrospective | Purpose: disease detection (local, nodal, metastatic) | True-positive by binary fashion | True-positive, 31% (28/91) |
| Endpoints: | ||||||
| Histopathology | ||||||
| Decrease in PSA after irradiation to primary site | ||||||
| Lesions assessed with CIMa | ||||||
| Follow-up CIM | ||||||
| Morris et al. (37), 2005 | 22 | Metastatic castration-resistant | Prospective | Purpose: outcome measure of treatment | Data analysis at 0, 4, and 12 wk of treatment | PET and clinical status correlated |
| Endpoints: | 4 wk, 91% | |||||
| Lesions assessed with CIMa | Test of discordance | 12 wk, 94% | ||||
| New lesions on PET | ||||||
| Patient followed until POD or death | ||||||
| Changes in SUV and PSA with treatment | ||||||
| Chang et al. (39), 2003 | 24 | Rising PSA | Retrospective | Purpose: disease detection (nodal) | Sensitivity, specificity | Sensitivity, 75% (12/16) |
| Endpoint: histopathology | Specificity, 100% | |||||
| Morris et al. (35), 2002 | 17 | Metastatic castration- sensitive and -resistant | Prospective | Purpose: disease detection (bone, soft tissue) | Lesion-based matched-pair data | Bone lesion, 71% seen on both PET and BS |
| Endpoints: | Soft-tissue lesion, 39% seen on both PET and CT/MRI | |||||
| Lesions assessed with CIMa | ||||||
| Follow-up CIMa |
CIM = conventional imaging modality; POD = progression of disease; SUV = standardized uptake value; BS = bone scan.